the Global Biosimilar pipeline” report has been added to ResearchAndMarkets.com’s
There are multiple biosimilars in development for a range of therapy
areas from cancer and diabetes to ophthalmology and respiratory.
High-value mAbs such as Roche’s Avastin (bevacizumab), Abbvie’s Humira
(adalimumab) and Janssen/Merck & Co’s Remicade (infliximab) are being
targeted by multiple biosimilar developers. But which companies are
leading the market? What products are being targeted? Where is
development geographically concentrated? What licensing and
collaboration opportunities are there?
What is the true potential of the much hyped biosimilar market?
At present there are 260 biosimilar products which are approved in at
least one market – and many of those are first generation products such
as hormones. The future, however, is looking more interesting with 188
biosimilars in development, 61 of which are in Phase III trials.
The number of high value mAbs for a wide range of conditions has
increased. Development continues to be concentrated in countries such as
India, China, Bangladesh, Iran and South Korea. In contrast, high
development cost, originator defence strategies and more stringent
regulatory regimes are pegging back development interest in the US and
In the US there are 6 companies with 8 biosimilars registered . The
sector is dominated by originator companies such as Pfizer, Amgen and
Merck & Co. Europe is scarcely better with 9 companies and 13
biosimilars registered. The global biosimilar market is maturing both in
its scope and ambitions.
Key Topics Covered:
1. Report methodology and objectives
3. Biosimilar pipeline by product
4. Biosimilar pipelines by company
For more information about this report visit https://www.researchandmarkets.com/research/gd8qdk/charting_the?w=4
View source version on businesswire.com: https://www.businesswire.com/news/home/20180615005799/en/